Ardelyx, Inc. (NASDAQ:ARDX) Stock Has Consensus Price Target of $13.90

Shares of Ardelyx, Inc. (NASDAQ:ARDX) have been assigned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $13.90.

A number of brokerages recently issued reports on ARDX. Wedbush reiterated an “outperform” rating and issued a $9.00 price objective on shares of Ardelyx in a report on Tuesday, August 18th. LADENBURG THALM/SH SH initiated coverage on Ardelyx in a report on Tuesday, June 16th. They set a “buy” rating and a $16.00 target price on the stock. Piper Sandler reduced their price target on Ardelyx from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Monday, August 17th. Citigroup reduced their price target on Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, TD Cowen decreased their price target on Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 7th.

Insider Transactions at Ardelyx

In other Ardelyx news, insider James Brady sold 15,136 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $58,424.96. Following the transaction, the insider owned 245,930 shares in the company, valued at $949,289.80. This trade represents a 5.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mike Kelliher sold 7,758 shares of Ardelyx stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $29,945.88. Following the completion of the transaction, the insider directly owned 349,660 shares in the company, valued at approximately $1,349,687.60. This represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 126,059 shares of company stock worth $486,588. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Ardelyx

Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Ardelyx in the 2nd quarter valued at approximately $119,874,000. Jupiter Topco LLC acquired a new position in shares of Ardelyx during the second quarter worth approximately $27,043,000. AIGH Capital Management LLC acquired a new position in shares of Ardelyx during the second quarter worth approximately $16,320,000. Bank of America Corp DE bought a new stake in shares of Ardelyx in the second quarter valued at approximately $11,034,000. Finally, Rubric Capital Management LP bought a new stake in shares of Ardelyx in the first quarter valued at approximately $11,147,000. 58.92% of the stock is owned by institutional investors.

Ardelyx Price Performance

NASDAQ ARDX opened at $3.42 on Wednesday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $852.23 million, a PE ratio of -15.55 and a beta of 0.70. Ardelyx has a 12-month low of $3.33 and a 12-month high of $8.40. The company has a 50 day moving average price of $4.10 and a two-hundred day moving average price of $5.26.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%.The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.08) EPS. As a group, equities analysts predict that Ardelyx will post -0.2 earnings per share for the current fiscal year.

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, producing a 0.0-day short-interest ratio. This suggests short selling is not currently a significant identifiable driver, although the figure may reflect a reporting anomaly.
• Negative Sentiment: Multiple firms—including Robbins LLP, Bronstein Gewirtz & Grossman, SBS Law, Rosen Law Firm, Pomerantz, Portnoy Law Firm, Kaplan Fox and SueWallSt—announced or reiterated a securities class action involving Ardelyx investors who purchased shares from January 13, 2025, through August 6, 2026. Investors have until November 16, 2026 to seek appointment as lead plaintiff. Robbins LLP class action reminder Bronstein Gewirtz & Grossman class action notice
• Negative Sentiment: The complaint reportedly alleges that Ardelyx and certain executives misled investors about commercial performance and growth, including whether the company’s patient-access strategy was effective. The allegations reference payer prior-authorization and step-edit requirements that allegedly restricted prescriptions for IBSRELA and XPHOZAH. These claims have not been proven, but the repeated notices increase legal, reputational and potential financial-risk concerns for shareholders. Rosen Law Firm investor notice SueWallSt lawsuit notice

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s lead product candidates and marketed medicines are designed to address disorders involving the regulation of phosphate and other substances in the digestive system.

Ardelyx markets XPHOZAH (tenapanor) in the United States for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Tenapanor works locally in the gastrointestinal tract by inhibiting the sodium/hydrogen exchanger 3, thereby reducing intestinal phosphate absorption.